{"nctId":"NCT00089505","briefTitle":"NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission","startDateStruct":{"date":"2006-11"},"conditions":["HIV Infections"],"count":745,"armGroups":[{"label":"NVP/NVP","type":"EXPERIMENTAL","interventionNames":["Drug: Emtricitabine","Drug: Emtricitabine/Tenofovir disoproxil fumarate","Drug: Nevirapine","Drug: Tenofovir disoproxil fumarate"]},{"label":"NVP/LPV_r","type":"EXPERIMENTAL","interventionNames":["Drug: Emtricitabine","Drug: Emtricitabine/Tenofovir disoproxil fumarate","Drug: Lopinavir/Ritonavir","Drug: Tenofovir disoproxil fumarate"]},{"label":"NoNVP/NVP","type":"EXPERIMENTAL","interventionNames":["Drug: Emtricitabine","Drug: Emtricitabine/Tenofovir disoproxil fumarate","Drug: Nevirapine","Drug: Tenofovir disoproxil fumarate"]},{"label":"NoNVP/LPV_r","type":"EXPERIMENTAL","interventionNames":["Drug: Emtricitabine","Drug: Emtricitabine/Tenofovir disoproxil fumarate","Drug: Lopinavir/Ritonavir","Drug: Tenofovir disoproxil fumarate"]}],"interventions":[{"name":"Emtricitabine","otherNames":["FTC"]},{"name":"Emtricitabine/Tenofovir disoproxil fumarate","otherNames":["FTC/TDF"]},{"name":"Lopinavir/Ritonavir","otherNames":["LPV/RTV"]},{"name":"Nevirapine","otherNames":["NVP"]},{"name":"Tenofovir disoproxil fumarate","otherNames":["TDF"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for All Participants:\n\n* HIV infected\n* CD4 count less than 200 cells/mm\\^3 within 90 days prior to study entry\n* Plasma HIV-1 RNA using standard Roche Amplicor HIV-1 Monitor Assay within 45 days prior to study entry\n* the following laboratory values obtained within 45 days prior to study entry: absolute neutrophil count\\>=750/mm\\^3;Hemoglobin\\>=7.0g/dL;platelet count\\>=50000/mm\\^3;aspartate aminotransferase (AST),Alanine aminotransferase (ALT), and alkaline phosphatase \\<=2.5 x ULN; total bilirubin \\<=2.5 x ULN\n* Normal renal function within 45 days prior to study entry\n* Willing to use acceptable forms of contraception\n* Karnofsky performance score \\>=70 on at least one occasion within 45 days prior to study entry\n* Parent or guardian willing to provide informed consent, if applicable\n* Planning to remain in the same geographical area of residence and are willing to attend study visits as required\n\nInclusion Criteria for Trial 1 Participants:\n\n* Previously received NVP for prevention of MTCT of HIV\n* Has documentation of all prior doses of NVP used for prevention of MTCT of HIV\n* Last dose of NVP for prevention of MTCT of HIV taken at least 6 months prior to study entry\n\nExclusion Criteria for All Participants:\n\n* Previously received any antiretrovirals, excluding NVP for MTCT prophylaxis for Trial 1 participants. Participants who have received up to 10 weeks of zidovudine alone and completed this course at least 6 months prior to study entry are not excluded.\n* Use of systemic cancer chemotherapy, systemic investigational agents, immunomodulators, or rifampin within 30 days of study entry\n* Pregnant or breastfeeding\n* Known allergy or sensitivity to study drugs or their formulations\n* Any condition, including drug or alcohol abuse, that, in the opinion of the investigator, may interfere with adherence to study regimens\n* Serious illness requiring systemic treatment or hospitalization. Participants who complete therapy or are clinically stable on therapy for at least 30 days prior to study entry are not excluded.\n* Tuberculosis (TB) treatment within 30 days prior to study entry\n* Use of any prohibited medications within 30 days prior to study entry\n* Involuntary incarceration in a correctional facility, prison, or jail for legal reasons or in a medical facility for treatment of either a psychiatric or physical illness","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"13 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants Who Experienced Virologic Failure or Died.","description":"Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is \\>=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG003","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants Who Experienced Virologic Failure or Died","description":"Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is \\>=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"CD4 Count Change From Randomization","description":"Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV\\_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV\\_r arms, since the follow-up continued as planned, data through overall study were used.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"201","spread":null},{"groupId":"OG002","value":"172","spread":null},{"groupId":"OG003","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"291","spread":null},{"groupId":"OG001","value":"278","spread":null},{"groupId":"OG002","value":"223","spread":null},{"groupId":"OG003","value":"256","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.","description":"The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV\\_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV\\_r arms, since the follow-up continued as planned, data through overall study were used.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced HIV-related Disease Progression or Death","description":"Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry","description":"5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is \\>=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry","description":"5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is \\>=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"132","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality","description":"Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)\\>=2.6 x ULN or alanine aminotransferase (ALT)\\>=2.6 x ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month","description":"Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV\\_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV\\_r arms, since the follow-up continued as planned, data through overall study were used.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"90","spread":null},{"groupId":"OG003","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"87","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":121},"commonTop":["Neutrophil count decreased","Rash","Cough","Headache","Blood sodium decreased"]}}}